کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2409936 | 1551797 | 2005 | 8 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs](/preview/png/2409936.png)
An attenuated recombinant herpes simplex virus type 2 (HSV-2), designated as AD472, was constructed by deleting both copies of the γ134.5 gene, UL55-56, UL43.5, and the US10–12 region from HSV-2 strain G. This virus was engineered to be a safe and effective live attenuated HSV-2 vaccine and was tested in the guinea pig model of genital herpes to evaluate its ability to protect from disease upon challenge with the wild type (wt) virus, HSV-2 (G). AD472 administered intramuscularly did not prevent infection or virus replication in the vaginal tract, but did reduce both lesion development and severity in a dose-dependent manner in guinea pigs challenged with the wt virus. Frequency of reactivation from latency was low compared with that of the parent virus, HSV-2 (G). Immunization with AD472 at doses of 1 × 105 PFU generally precluded colonization of the ganglia or establishment of latency by the challenge virus. Results presented here support the concept of a rationally engineered live attenuated vaccine for the prevention of the genital disease associated with infection by HSV-2.
Journal: Vaccine - Volume 23, Issues 46–47, 16 November 2005, Pages 5424–5431